Oncolytic virus-mediated p53 overexpression promotes systemic antitumor immune response in osteosarcoma

2021 Fiscal Year Final Research Report

• Project/Area Number: 19K23888
• Research Category: Grant-in-Aid for Research Activity Start-up
• Allocation Type: Multi-year Fund
• Review Section: 0901:Oncology and related fields
• Research Institution: Okayama University
• Principal Investigator: Kondo Hiroya 岡山大学, 大学病院, 医員 (40846911)
• Project Period (FY): 2019-08-30 – 2022-03-31
• Keywords: 腫瘍融解ウイルス療法 / p53 / 骨肉腫 / 免疫原性細胞死

Outline of Final Research Achievements

Although p53 itself was involved in immunogenic cell death, OBP-702 actually showed tumor immune activity against a vivo model. In addition, the abscopal effect on distant tumors was demonstrated, and it is expected to be applied to the simultaneous treatment of primary and distant tumors with tumor-dissolving viral agents, which have been used only for local treatment. In addition, the antitumor effect is expected to be mediated by activation of the immune response throughout the body, which may lead to potential applications such as combination therapy with immune chuck point inhibitors such as anti-PD-1. The results of this study are very significant, as they leave open the possibility of therapeutic applications and the expansion of research themes.

Free Research Field

腫瘍

Academic Significance and Societal Importance of the Research Achievements

骨軟部肉腫は系統的化学療法の導入によりその予後は改善してきたが、化学・放射線療法抵抗例や転移例など、予後不良例も多い。そのため、骨軟部肉腫に対する新規治療法の開発が重要な課題である。近年、抗PD-1抗体等、腫瘍免疫療法に対する研究が盛んに行われており、骨軟部肉腫治療の発展の為にも腫瘍免疫療法は非常に重要である。骨肉腫においては免疫細胞の乏しいcold tumorが主体と考えられてきたが、腫瘍融解アデノウイルス製剤投与におけるcold tumorからhot tumorへの転換することができるのであればますます治療応用の可能性が高まる。